A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
about
Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effectsWhy sex matters: the biological mechanisms of cardiovascular disease.Progestogen effects at vascular level: the endothelial cells.One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women.
P2860
A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
@en
A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
@nl
type
label
A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
@en
A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
@nl
prefLabel
A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
@en
A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
@nl
P2860
P1433
P1476
A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
@en
P2093
A R Genazzani
P2860
P356
10.3109/13697130903437375
P577
2010-02-01T00:00:00Z